Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

被引：218
|
作者：
Kerr, K. M. [1 ,2 ]
Bubendorf, L. [3 ]
Edelman, M. J. [4 ]
Marchetti, A. [5 ]
Mok, T. [6 ]
Novello, S. [7 ]
O'Byrne, K. [8 ,9 ]
Stahel, R. [10 ]
Peters, S. [11 ]
Felip, E. [12 ]
机构：
[1] Aberdeen Royal Infirm, Dept Pathol, Aberdeen, Scotland
[2] Aberdeen Univ Med Sch, Aberdeen, Scotland
[3] Univ Basel Hosp, Inst Pathol, CH-4031 Basel, Switzerland
[4] Univ New Mexico Canc Ctr, Albuquerque, NM USA
[5] Univ Fdn, Ctr Predict Mol Med, Ctr Excellence Ageing, Chieti, Italy
[6] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China
[7] Univ Turin, Azienda Osped Univ San Luigi Orbassano, Dept Oncol, Thorac Oncol Unit, I-10124 Turin, Italy
[8] Trinity Coll Dublin, Dublin, Ireland
[9] Queensland Univ Technol, Brisbane, Qld 4001, Australia
[10] Univ Zurich Hosp, Clin Oncol, CH-8091 Zurich, Switzerland
[11] CHU Vaudois, Dept Oncol, Lausanne, Switzerland
[12] Vall dHebron Univ Hosp, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷 / 09期
关键词：
ESMO; consensus; non-small-cell lung cancer; pathology; molecular testing; recommendations; MESSENGER-RNA EXPRESSION; IN-SITU HYBRIDIZATION; EXTERNAL QUALITY ASSESSMENT; FACTOR RECEPTOR MUTATIONS; ALK GENE REARRANGEMENTS; EML4-ALK FUSION GENE; PHASE-III TRIAL; BRONCHIAL BIOPSY; INTERNATIONAL-ASSOCIATION; HISTOLOGICAL CLASSIFICATION;
D O I：
10.1093/annonc/mdu145
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas.
引用
收藏
页码：1681 / 1690
页数：10
相关论文
共 50 条
  • [1] Molecular pathology of non-small-cell lung cancer
    Breuer, RHJ
    Postmus, PE
    Smit, EF
    RESPIRATION, 2005, 72 (03) : 313 - 330
  • [2] 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer
    Eberhardt, W. E. E.
    De Ruysscher, D.
    Weder, W.
    Le Pechoux, C.
    De Leyn, P.
    Hoffmann, H.
    Westeel, V.
    Stahel, R.
    Felip, E.
    Peters, S.
    ANNALS OF ONCOLOGY, 2015, 26 (08) : 1573 - 1588
  • [3] Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010
    Felip, E.
    Gridelli, C.
    Baas, P.
    Rosell, R.
    Stahel, R.
    VETERINARY RECORD, 2011, 169 (19) : 1507 - 1519
  • [4] 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease
    Besse, B.
    Adjei, A.
    Baas, P.
    Meldgaard, P.
    Nicolson, M.
    Paz-Ares, L.
    Reck, M.
    Smit, E. F.
    Syrigos, K.
    Stahel, R.
    Felip, E.
    Peters, S.
    ANNALS OF ONCOLOGY, 2014, 25 (08) : 1475 - 1484
  • [5] ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
    Passaro, A.
    Leighl, N.
    Blackhall, F.
    Popat, S.
    Kerr, K.
    Ahn, M. J.
    Arcila, M. E.
    Arrieta, O.
    Planchard, D.
    de Marinis, F.
    Dingemans, A. M.
    Dziadziuszko, R.
    Faivre-Finn, C.
    Feldman, J.
    Felip, E.
    Curigliano, G.
    Herbst, R.
    Janne, P. A.
    John, T.
    Mitsudomi, T.
    Mok, T.
    Normanno, N.
    Paz-Ares, L.
    Ramalingam, S.
    Sequist, L.
    Vansteenkiste, J.
    Wistuba, I. I.
    Wolf, J.
    Wu, Y. L.
    Yang, S. R.
    Yang, J. C. H.
    Yatabe, Y.
    Pentheroudakis, G.
    Peters, S.
    ANNALS OF ONCOLOGY, 2022, 33 (05) : 466 - 487
  • [6] 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
    Vansteenkiste, J.
    Crino, L.
    Dooms, C.
    Douillard, J. Y.
    Faivre-Finn, C.
    Lim, E.
    Rocco, G.
    Senan, S.
    Van Schil, P.
    Veronesi, G.
    Stahel, R.
    Peters, S.
    Felip, E.
    ANNALS OF ONCOLOGY, 2014, 25 (08) : 1462 - 1474
  • [7] 1st ESMO Consensus Conference in lung cancer; Lugano 2010: Small-cell lung cancer
    Stahel, R.
    Thatcher, N.
    Frueh, M.
    Le Pechoux, C.
    Postmus, P. E.
    Sorensen, J. B.
    Felip, E.
    ANNALS OF ONCOLOGY, 2011, 22 (09) : 1973 - 1980
  • [8] Molecular and Clinical Analysis of Predictive Biomarkers in Non-Small-Cell Lung Cancer
    Passaro, A.
    Palazzo, A.
    Trenta, P.
    Mancini, M. L.
    Morano, F.
    Cortesi, E.
    CURRENT MEDICINAL CHEMISTRY, 2012, 19 (22) : 3689 - 3700
  • [9] Biomarkers of response to gefitinib in non-small-cell lung cancer
    Carbone, David P.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2004, 1 (02): : 66 - 67
  • [10] Potential biomarkers for immunotherapy in non-small-cell lung cancer
    Wang, Xing
    Qiao, Ziyun
    Aramini, Beatrice
    Lin, Dong
    Li, Xiaolong
    Fan, Jiang
    CANCER AND METASTASIS REVIEWS, 2023, 42 (03) : 661 - 675
12345